» Articles » PMID: 17142309

Novel Patterns of Genome Rearrangement and Their Association with Survival in Breast Cancer

Abstract

Representational Oligonucleotide Microarray Analysis (ROMA) detects genomic amplifications and deletions with boundaries defined at a resolution of approximately 50 kb. We have used this technique to examine 243 breast tumors from two separate studies for which detailed clinical data were available. The very high resolution of this technology has enabled us to identify three characteristic patterns of genomic copy number variation in diploid tumors and to measure correlations with patient survival. One of these patterns is characterized by multiple closely spaced amplicons, or "firestorms," limited to single chromosome arms. These multiple amplifications are highly correlated with aggressive disease and poor survival even when the rest of the genome is relatively quiet. Analysis of a selected subset of clinical material suggests that a simple genomic calculation, based on the number and proximity of genomic alterations, correlates with life-table estimates of the probability of overall survival in patients with primary breast cancer. Based on this sample, we generate the working hypothesis that copy number profiling might provide information useful in making clinical decisions, especially regarding the use or not of systemic therapies (hormonal therapy, chemotherapy), in the management of operable primary breast cancer with ostensibly good prognosis, for example, small, node-negative, hormone-receptor-positive diploid cases.

Citing Articles

Classification of Breast Cancer Through the Perspective of Cell Identity Models.

Iggo R, MacGrogan G Adv Exp Med Biol. 2025; 1464():185-207.

PMID: 39821027 DOI: 10.1007/978-3-031-70875-6_11.


Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma.

Mariotto E, Rampazzo E, Bortolozzi R, Rruga F, Zeni I, Manfreda L Acta Neuropathol Commun. 2023; 11(1):183.

PMID: 37978570 PMC: 10655385. DOI: 10.1186/s40478-023-01679-7.


Deciphering complex breakage-fusion-bridge genome rearrangements with Ambigram.

Li C, Chen L, Pan G, Zhang W, Cheng Li S Nat Commun. 2023; 14(1):5528.

PMID: 37684230 PMC: 10491683. DOI: 10.1038/s41467-023-41259-w.


Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progression.

Batista M, Roffe M, Romero I, Lopez-Guerrero J, Illueca C, Lopez R BMC Cancer. 2023; 23(1):613.

PMID: 37400764 PMC: 10316635. DOI: 10.1186/s12885-023-11095-8.


ERα-associated translocations underlie oncogene amplifications in breast cancer.

Lee J, Jung Y, Cheong T, Espejo Valle-Inclan J, Chu C, Gulhan D Nature. 2023; 618(7967):1024-1032.

PMID: 37198482 PMC: 10307628. DOI: 10.1038/s41586-023-06057-w.


References
1.
Kronenwett U, Huwendiek S, Ostring C, Portwood N, Roblick U, Pawitan Y . Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res. 2004; 64(3):904-9. DOI: 10.1158/0008-5472.can-03-2451. View

2.
McCLINTOCK B . The Stability of Broken Ends of Chromosomes in Zea Mays. Genetics. 1941; 26(2):234-82. PMC: 1209127. DOI: 10.1093/genetics/26.2.234. View

3.
Ormandy C, Musgrove E, Hui R, Daly R, Sutherland R . Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003; 78(3):323-35. DOI: 10.1023/a:1023033708204. View

4.
Knoop A, Knudsen H, Balslev E, Rasmussen B, Overgaard J, Nielsen K . retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:.... J Clin Oncol. 2005; 23(30):7483-90. DOI: 10.1200/JCO.2005.11.007. View

5.
Navin N, Grubor V, Hicks J, Leibu E, Thomas E, Troge J . PROBER: oligonucleotide FISH probe design software. Bioinformatics. 2006; 22(19):2437-8. DOI: 10.1093/bioinformatics/btl273. View